RU2637088C2 - Лечение инфаркта миокарда с использованием антагонистов tgf-бета - Google Patents

Лечение инфаркта миокарда с использованием антагонистов tgf-бета Download PDF

Info

Publication number
RU2637088C2
RU2637088C2 RU2013114365A RU2013114365A RU2637088C2 RU 2637088 C2 RU2637088 C2 RU 2637088C2 RU 2013114365 A RU2013114365 A RU 2013114365A RU 2013114365 A RU2013114365 A RU 2013114365A RU 2637088 C2 RU2637088 C2 RU 2637088C2
Authority
RU
Russia
Prior art keywords
tgf
antibody
antagonist
domain
antibodies
Prior art date
Application number
RU2013114365A
Other languages
English (en)
Russian (ru)
Other versions
RU2013114365A (ru
Inventor
Джеффри И. АКИТА
Скот ЛОННИНГ
Ричард К. Мл. ГРЕГОРИ
Амелия Б. КУДЕЙ
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of RU2013114365A publication Critical patent/RU2013114365A/ru
Application granted granted Critical
Publication of RU2637088C2 publication Critical patent/RU2637088C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
RU2013114365A 2010-09-01 2011-09-01 Лечение инфаркта миокарда с использованием антагонистов tgf-бета RU2637088C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01
US61/379,315 2010-09-01
PCT/US2011/001536 WO2012030394A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Publications (2)

Publication Number Publication Date
RU2013114365A RU2013114365A (ru) 2014-10-10
RU2637088C2 true RU2637088C2 (ru) 2017-11-29

Family

ID=44654454

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013114365A RU2637088C2 (ru) 2010-09-01 2011-09-01 Лечение инфаркта миокарда с использованием антагонистов tgf-бета

Country Status (19)

Country Link
US (2) US20130330352A1 (https=)
EP (1) EP2611831B1 (https=)
JP (2) JP6377348B2 (https=)
KR (1) KR101939965B1 (https=)
CN (1) CN103201292B (https=)
BR (1) BR112013004850B1 (https=)
CA (1) CA2809568C (https=)
CL (1) CL2013000586A1 (https=)
ES (1) ES2715177T3 (https=)
IL (1) IL225018A (https=)
MX (1) MX354535B (https=)
MY (1) MY165160A (https=)
NZ (2) NZ608813A (https=)
PH (1) PH12013500411A1 (https=)
PL (1) PL2611831T3 (https=)
RU (1) RU2637088C2 (https=)
SG (2) SG187953A1 (https=)
TR (1) TR201903101T4 (https=)
WO (1) WO2012030394A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008628A2 (pt) * 2009-02-18 2016-03-01 Cormatrix Cardiovascular Inc método de tratamento ou prevenção de arritmia cardíaca em um indivíduo
PT2971048T (pt) * 2013-03-11 2019-02-06 Genzyme Corp Anticorpos anti-tgf-beta manipulados e fragmentos de ligação a antigénios
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
HK1256638A1 (zh) 2015-08-04 2019-09-27 Acceleron Pharma Inc. 用於治疗骨髓增生性病症的方法
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
TW201726744A (zh) 2016-01-11 2017-08-01 奧托德里克有限公司 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ，インコーポレイテッド ＴＧＦ−βアンタゴニストコンジュゲート
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
AU2021339468A1 (en) * 2020-09-10 2023-03-30 Implicit Bioscience Limited Therapeutic methods and agents for the treatment of myocardial infarction
US20250034212A1 (en) 2021-09-30 2025-01-30 Peptidream Inc. Peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2006083779A2 (en) 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
WO2006086469A2 (en) * 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELLMERS L.J. et al. "Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after meocardial infarction". Endocrinology, 2008, Nov; 149(11):5828-34, найдено из Интернет: http://press.endocrine.org/doi/10.1210/en.2008-0165?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed;. *
ELLMERS L.J. et al. "Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after meocardial infarction". Endocrinology, 2008, Nov; 149(11):5828-34, найдено из Интернет: http://press.endocrine.org/doi/10.1210/en.2008-0165?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed;. OKADA H. et al. "Postinfarction gene therapy against transforming growth factor-β signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failute". Circulation, 2005; 111:2430-2437, найдено 04.08.2015, найдено из Интернет: http://ajpheart.physiology.org/content/297/4/H1504.long.FRANTZ S. et al. "Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction". Basic. Res. Cardiol. 2008, Sep; 103(5):485-92, реферат, найдено 01.12.2015, найдено из PubMed PMID:18651091. *
FRANTZ S. et al. "Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction". Basic. Res. Cardiol. 2008, Sep; 103(5):485-92, , найдено 01.12.2015, найдено из PubMed PMID:18651091. *
OKADA H. et al. "Postinfarction gene therapy against transforming growth factor-β signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failute". Circulation, 2005; 111:2430-2437, найдено 04.08.2015, найдено из Интернет: http://ajpheart.physiology.org/content/297/4/H1504.long. *

Also Published As

Publication number Publication date
TR201903101T4 (tr) 2019-03-21
PL2611831T3 (pl) 2019-05-31
US20130330352A1 (en) 2013-12-12
JP6377348B2 (ja) 2018-08-22
CA2809568C (en) 2019-06-11
CN103201292A (zh) 2013-07-10
CL2013000586A1 (es) 2013-08-30
KR101939965B1 (ko) 2019-01-18
NZ608813A (en) 2014-11-28
MX2013002390A (es) 2013-08-27
WO2012030394A1 (en) 2012-03-08
CA2809568A1 (en) 2012-03-08
CN103201292B (zh) 2016-09-14
EP2611831A1 (en) 2013-07-10
ES2715177T3 (es) 2019-06-03
KR20130111550A (ko) 2013-10-10
SG10201506909PA (en) 2015-10-29
PH12013500411A1 (en) 2022-03-30
IL225018A (en) 2017-11-30
US20170233465A1 (en) 2017-08-17
SG187953A1 (en) 2013-03-28
EP2611831B1 (en) 2018-12-12
MY165160A (en) 2018-02-28
JP2017193543A (ja) 2017-10-26
BR112013004850B1 (pt) 2020-04-07
JP2013542179A (ja) 2013-11-21
RU2013114365A (ru) 2014-10-10
BR112013004850A2 (pt) 2016-05-31
US10633437B2 (en) 2020-04-28
NZ624382A (en) 2015-05-29
AU2011296574B2 (en) 2015-12-03
MX354535B (es) 2018-03-09
AU2011296574A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
RU2637088C2 (ru) Лечение инфаркта миокарда с использованием антагонистов tgf-бета
JP6463807B2 (ja) ＴＧＦβに対する抗体
US8753627B2 (en) Anti-activin a antibodies and uses thereof
HK1245111A1 (zh) IL-1β抗体及其结合片段的心血管相关用途
CN105431455A (zh) 抗激活素a化合物对受试者的施用
AU2017320989A9 (en) Anti-gremlin-1 (GREM1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
AU2011296574B9 (en) Treatment of myocardial infarction using TGF - beta antagonists
HK1181788A (en) Treatment of myocardial infarction using tgf - beta antagonists
HK1181788B (en) Treatment of myocardial infarction using tgf - beta antagonists
HK1187356B (en) Treatment of myocardial infarction using tgf - beta antagonists
HK1187356A (en) Treatment of myocardial infarction using tgf - beta antagonists
HK1201859B (zh) 针对TGFβ的抗体
HK1201860B (en) Antibodies to tgfbeta